Surgical Science (Buy, TP: SEK218.00) - Turning the page on 2024 – starting with an acquisition
Following a change of analyst, we have updated our model and cut our target price to SEK218 (225), but reiterate our BUY on what we view is a still-solid case fundamentally. For Q4, we forecast 14% total revenue growth YOY and EBITDA of SEK69m, for a 27% margin.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.